3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
9
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
9
Leukemia, Myeloid, Acute
7
Lymphoma
5
Leukemia
5
Lymphoma, Non-Hodgkin
4
Leukemia, Biphenotypic, Acute
4
Squamous Cell Carcinoma of Head and Neck
3
Myelodysplastic Syndromes
3
Multiple Myeloma
3
Head and Neck Neoplasms
3
Stomach Neoplasms
2
Recurrence
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Neoplasm Metastasis
2
Melanoma
2
Lymphoma, Mantle-Cell
2
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
Leukemia, B-Cell
2
Hodgkin Disease
2
Carcinoma, Non-Small-Cell Lung
2
Anemia, Refractory, with Excess of Blasts
2
Uveal Melanoma
1
Triple Negative Breast Neoplasms
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
1
Ovarian Neoplasms
1
Oropharyngeal Neoplasms
1
Neoplasms
1
Neoplasm, Residual
1
Lymphoma, T-Cell, Cutaneous
1
Interventions
blinatumomab
5
midostaurin
2
Azacitidine
2
venetoclax
1
tisagenlecleucel
1
siremadlin
1
sabatolimab
1
pulrodemstat besilate
1
posaconazole
1
fludarabine phosphate
1
fludarabine
1
Zoledronic Acid
1
Vitamin D
1
N,N-dicyclohexyl-isoborneol-10-sulfonamide
1
Midazolam
1
Idarubicin
1
Drug Therapy
1
Daunorubicin
1
Cytarabine
1
Cyclophosphamide
1
Calcium
1
CD3 Complex
1
Anthracyclines
1
AP 1903 reagent
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Neoplasm, Residual
×
fludarabine phosphate
×
Clear all
NCT06500273
2026-06-02
ALPHA3
Allogene Therapeutics
Phase 2
Recruiting
250 enrolled